OBJECTIVE: Comprehensive analysis of the 9p21 locus including the CDKN2A, ARF, and CDKN2B genes in 53 individuals from melanoma index cases considered to be at heightened risk of melanoma. METHODS AND RESULTS: Using a combination of DNA sequencing, gene copy number by real time quantitative PCR, linkage analysis, and transcript analysis in haploid somatic cell hybrids, we found no evidence for germline alteration in either coding or non-coding domains of CDKN2A and CDKN2B. However, we identified a p14ARF exon 1beta missense germline mutation (G16D) in a melanoma-neural system tumour syndrome (CMM+NST) family and a 8474 bp germline deletion from 196 bp upstream of p14ARF exon 1beta initiation codon to 11233 bp upstream of exon 1alpha of p16(INK4A) in a family with five melanoma cases. For three out of 10 families with at least three melanoma cases, the disease gene was unlinked to the 9p21 region, while linkage analysis was not fully conclusive for seven families. CONCLUSIONS: These data reinforce the hypothesis that ARF is a melanoma susceptibility gene and suggest that germline deletions specifically affecting p14ARF may not be solely responsible for NST susceptibility. Predisposition to CMM+NST could either be due to complete disruption of the CDKN2A locus or be the result of more complex genetic inheritance. In addition, the absence of any genetic alteration in 50 melanoma prone families or patients suggests the presence of additional tumour suppressor genes possibly in the 9p21 region, and on other chromosomes.
OBJECTIVE: Comprehensive analysis of the 9p21 locus including the CDKN2A, ARF, and CDKN2B genes in 53 individuals from melanoma index cases considered to be at heightened risk of melanoma. METHODS AND RESULTS: Using a combination of DNA sequencing, gene copy number by real time quantitative PCR, linkage analysis, and transcript analysis in haploid somatic cell hybrids, we found no evidence for germline alteration in either coding or non-coding domains of CDKN2A and CDKN2B. However, we identified a p14ARF exon 1beta missense germline mutation (G16D) in a melanoma-neural system tumour syndrome (CMM+NST) family and a 8474 bp germline deletion from 196 bp upstream of p14ARF exon 1beta initiation codon to 11233 bp upstream of exon 1alpha of p16(INK4A) in a family with five melanoma cases. For three out of 10 families with at least three melanoma cases, the disease gene was unlinked to the 9p21 region, while linkage analysis was not fully conclusive for seven families. CONCLUSIONS: These data reinforce the hypothesis that ARF is a melanoma susceptibility gene and suggest that germline deletions specifically affecting p14ARF may not be solely responsible for NST susceptibility. Predisposition to CMM+NST could either be due to complete disruption of the CDKN2A locus or be the result of more complex genetic inheritance. In addition, the absence of any genetic alteration in 50 melanoma prone families or patients suggests the presence of additional tumour suppressor genes possibly in the 9p21 region, and on other chromosomes.
Authors: Elizabeth Gillanders; Suh-Hang Hank Juo; Elizabeth A Holland; MaryPat Jones; Derek Nancarrow; Diana Freas-Lutz; Raman Sood; Naeun Park; Mezbah Faruque; Carol Markey; Richard F Kefford; Jane Palmer; Wilma Bergman; D Timothy Bishop; Margaret A Tucker; Brigitte Bressac-de Paillerets; Johan Hansson; Mitchell Stark; Nelleke Gruis; Julia Newton Bishop; Alisa M Goldstein; Joan E Bailey-Wilson; Graham J Mann; Nicholas Hayward; Jeffrey Trent Journal: Am J Hum Genet Date: 2003-07-03 Impact factor: 11.025
Authors: Jamileh Hashemi; Mikael S Lindström; Charlotte Asker; Anton Platz; Johan Hansson; Klas G Wiman Journal: Cancer Lett Date: 2002-06-28 Impact factor: 8.679
Authors: Joni L Rutter; Alisa M Goldstein; Michael R Dávila; Margaret A Tucker; Jeffery P Struewing Journal: Oncogene Date: 2003-07-10 Impact factor: 9.867
Authors: Dong Yin; Dong Xie; Wolf-Karsten Hofmann; Carl W Miller; Keith L Black; H Phillip Koeffler Journal: Oncogene Date: 2002-11-28 Impact factor: 9.867
Authors: D Timothy Bishop; Florence Demenais; Alisa M Goldstein; Wilma Bergman; Julia Newton Bishop; Brigitte Bressac-de Paillerets; Agnès Chompret; Paola Ghiorzo; Nelleke Gruis; Johan Hansson; Mark Harland; Nicholas Hayward; Elizabeth A Holland; Graham J Mann; Michela Mantelli; Derek Nancarrow; Anton Platz; Margaret A Tucker Journal: J Natl Cancer Inst Date: 2002-06-19 Impact factor: 13.506
Authors: Soo-Hyun Kim; Michael Mitchell; Hideta Fujii; Susana Llanos; Gordon Peters Journal: Proc Natl Acad Sci U S A Date: 2002-12-27 Impact factor: 11.205
Authors: Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond Journal: J Clin Invest Date: 2010-06-07 Impact factor: 14.808
Authors: Allen Mo; Stephen Jackson; Kamini Varma; Alan Carpino; Charles Giardina; Thomas J Devers; Daniel W Rosenberg Journal: Mol Cancer Res Date: 2016-06-27 Impact factor: 5.852
Authors: V K Goel; N Ibrahim; G Jiang; M Singhal; S Fee; T Flotte; S Westmoreland; F S Haluska; P W Hinds; F G Haluska Journal: Oncogene Date: 2009-04-27 Impact factor: 9.867
Authors: Daniel E Freedberg; Sushila H Rigas; Julie Russak; Weiming Gai; Margarita Kaplow; Iman Osman; Faye Turner; Juliette A Randerson-Moor; Alan Houghton; Klaus Busam; D Timothy Bishop; Boris C Bastian; Julia A Newton-Bishop; David Polsky Journal: J Natl Cancer Inst Date: 2008-05-27 Impact factor: 13.506
Authors: Nicole D Facompre; Pavithra Rajagopalan; Varun Sahu; Alexander T Pearson; Kathleen T Montone; Claire D James; Frederico O Gleber-Netto; Gregory S Weinstein; Jalal Jalaly; Alexander Lin; Anil K Rustgi; Hiroshi Nakagawa; Joseph A Califano; Curtis R Pickering; Elizabeth A White; Bradford E Windle; Iain M Morgan; Roger B Cohen; Phyllis A Gimotty; Devraj Basu Journal: Int J Cancer Date: 2020-07-06 Impact factor: 7.396